Presentation Information

Domperidone and Breastfeeding

• Speaker: Dr. Frank Nice , RPh, DPA,CPHP
• Presentation Type:
• Duration: 60 Mins
• Credits: 1 CERP, 1 Nursing CEU, 1 CME, 0.1 Midwifery CEU, 1 Dietetic CEU

Abstract:

Domperidone currently is used worldwide as an anti-nausea agent for adults, children, and women. It is currently available in 60 countries including Canada and Mexico. Domperidone was recently given orphan drug designation for the treatment of hypoprolactinemia in breastfeeding. Over 60,000 cases of hypoprolactinemia are reported annual in the United States. Infants who do not receive human milk cost the healthcare system over $13 billion each year and result in over 900 unnecessary infant deaths annually. Domperidone can produce significant increases in prolactin with subsequent increases in milk production. No drug is currently approved for the condition of hypoprolactinemia of lactation in any country.

This presentation will describe and explain the Orphan Drug Act and the steps necessary for domperidone to receive approval under the Act. Prolactin facts will be discussed as well as a review of the rare disease, hypoprolactinemia. The scientific rationale for the use of domperidone will be covered. Practical information will be presented on domperidone dosing and withdrawal of the drug with sufficient milk supply and with insufficient milk supply.